163 related articles for article (PubMed ID: 37463111)
1.
De Leo S; Trevisan M; Re Sartò GV; Moneta C; Pirovano M; Colombo C; Cosmai L; Fugazzola L
Thyroid; 2023 Sep; 33(9):1130-1132. PubMed ID: 37463111
[No Abstract] [Full Text] [Related]
2. Successful Treatment with Selpercatinib for Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer.
Ragnarsson O; Piasecka M; Hallqvist A
Curr Oncol; 2022 May; 29(5):3494-3498. PubMed ID: 35621672
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.
Højer Wang L; Wehland M; Wise PM; Infanger M; Grimm D; Kreissl MC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768635
[TBL] [Abstract][Full Text] [Related]
4. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
Seib CD; Beck TC; Kebebew E
Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
[TBL] [Abstract][Full Text] [Related]
5. Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report.
Matrone A; Prete A; Sartini MS; Elisei R
Ann Oncol; 2021 Nov; 32(11):1447-1449. PubMed ID: 34419556
[No Abstract] [Full Text] [Related]
6. Current Guidelines for Management of Medullary Thyroid Carcinoma.
Kim M; Kim BH
Endocrinol Metab (Seoul); 2021 Jun; 36(3):514-524. PubMed ID: 34154310
[TBL] [Abstract][Full Text] [Related]
7. Mouse models of medullary thyroid cancer and developing new targeted therapies.
Paragliola RM; Torino F; Papi G; Locantore P; Pontecorvi A; Corsello SM
Expert Opin Drug Discov; 2016 Oct; 11(10):917-9. PubMed ID: 27541085
[No Abstract] [Full Text] [Related]
8. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib.
Prete A; Gambale C; Cappagli V; Bottici V; Rossi P; Caciagli M; Papini P; Taddei D; Ortori S; Gabbrielli L; Celi A; Materazzi G; Elisei R; Matrone A
Eur J Endocrinol; 2022 Dec; 187(6):905-915. PubMed ID: 36314655
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
[TBL] [Abstract][Full Text] [Related]
10. Update on Targeted Therapy in Medullary Thyroid Cancer.
Okafor C; Hogan J; Raygada M; Thomas BJ; Akshintala S; Glod JW; Del Rivero J
Front Endocrinol (Lausanne); 2021; 12():708949. PubMed ID: 34489865
[TBL] [Abstract][Full Text] [Related]
11. Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).
ESMO Guidelines Committee
Ann Oncol; 2018 Oct; 29(Suppl 4):iv257-iv258. PubMed ID: 30285217
[No Abstract] [Full Text] [Related]
12. Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Milner TD; Ronghe M; Shaikh MG; MacGregor FB; Reed N
J Pediatr Hematol Oncol; 2019 Jul; 41(5):e329-e332. PubMed ID: 30334899
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V
Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023
[TBL] [Abstract][Full Text] [Related]
14. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.
Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
[TBL] [Abstract][Full Text] [Related]
15. Selpercatinib.
Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
[No Abstract] [Full Text] [Related]
16. Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.
Marques P; Vieira Mda S; Bugalho MJ
Endocrine; 2015 May; 49(1):290-2. PubMed ID: 25022661
[No Abstract] [Full Text] [Related]
17. Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
Di Molfetta S; Dotto A; Fanciulli G; Florio T; Feola T; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():667784. PubMed ID: 33935977
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.
Jalalat SZ; Cohen PR
Int J Dermatol; 2015 Jun; 54(6):e213-6. PubMed ID: 25040327
[No Abstract] [Full Text] [Related]
19. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
20. [New therapies in thyroid cancer].
López Mondéjar P; Galofré JC
Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
[No Abstract] [Full Text] [Related]
[Next] [New Search]